National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

Simple item page
dc.contributor.authorDursun, A
dc.contributor.authorBavbek, S
dc.contributor.authorMisirligil, Z
dc.contributor.authorErdener, F
dc.contributor.authorBuyukozturk, S
dc.contributor.authorAydin, O
dc.contributor.authorGemicioglu, B
dc.contributor.authorBayrak, P
dc.contributor.authorErkekol, FO
dc.contributor.authorYildirim, Z
dc.contributor.authorCilli, A
dc.contributor.authorBoz, AB
dc.contributor.authorAlpaydyn, AO
dc.contributor.authorKarakoc, G
dc.contributor.authorGorguner, M
dc.contributor.authorKarakaya, G
dc.contributor.authorIsik, R
dc.contributor.authorSapan, N
dc.contributor.authorBakirtas, A
dc.date.accessioned2025-04-10T10:37:17Z
dc.date.available2025-04-10T10:37:17Z
dc.identifier.e-issn1398-9995
dc.identifier.issn0105-4538
dc.identifier.urihttp://hdl.handle.net/20.500.14701/42944
dc.language.isoEnglish
dc.titleNational safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey
dc.typeMeeting Abstract

Files

Collections

Web of Science Koleksiyonu